SCHEMBL20135280

SCHEMBL20135280

COc1cc(C(=O)O)c(C)cc1C1(C(C)C)NC(=O)NC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.35
FYN P06241 1/20 0.35
MYC P01106 1/20 0.34
HPGD P15428 3/20 0.34
MAPT P10636 2/20 0.34
HSD17B10 Q99714 2/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34
ADAM17 P78536 4/20 0.32
ADAMTS5 Q9UNA0 4/20 0.32
ADAMTS4 O75173 2/20 0.32
KDM4E B2RXH2 4/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MMP2 P08253 1/20 0.32
MAPK1 P28482 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135013 0.87 ADAMTS5 (0.35) LCKFYNADAM17ADAMTS5ADAMTS4
SCHEMBL29688586 0.84 KDM4E (0.35) HPGDHSD17B10TSHRADAM17ADAMTS5
SCHEMBL20135169 0.84 KDM4E (0.35) HPGDHSD17B10TSHRADAM17ADAMTS5
SCHEMBL20135032 0.81 CA12 (0.47) TSHRKDM4ENPSR1MAPK1CA12
SCHEMBL29688564 0.81 TSHR (0.33) MAPTTSHRADAM17ADAMTS5NPSR1
SCHEMBL20135358 0.81 TSHR (0.33) MAPTTSHRADAM17ADAMTS5NPSR1
SCHEMBL20135592 0.78 ESRRA (0.34) ADAM17ADAMTS5MMP2
SCHEMBL29688519 0.75 SLC6A9 (0.37) HPGDMAPTHSD17B10POLBTSHR
SCHEMBL20135589 0.75 SLC6A9 (0.37) HPGDMAPTHSD17B10POLBTSHR
SCHEMBL20135157 0.71 CA12 (0.46) TSHRKDM4ENPSR1MAPK1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 LCK 2962/4885FYN 3198/4885MYC 4855/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 LCK 2430/4885FYN 3132/4885MYC 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.